Difference between revisions of "Cytarabine liposomal (DepoCyt)"
(updated content) |
m |
||
Line 19: | Line 19: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
− | [[Category: | + | [[Category:Pyrimidine analogs]] |
[[Category:DNA synthesis inhibitors]] | [[Category:DNA synthesis inhibitors]] | ||
[[Category:Irritant chemotherapy]] | [[Category:Irritant chemotherapy]] | ||
+ | |||
+ | [[Category:Drugs FDA approved in 1999]] |
Revision as of 15:21, 8 November 2014
Also known as Liposomal Ara-C.
General information
Class/mechanism: Pyrimidine analog, mimics cytosine. Converted intracellularly into cytarabine-5-triphosphate (ara-CTP). Exact mechanism of action not known; believed to inhibit DNA polymerase, incorporate into DNA and RNA, and kill cells undergoing DNA synthesis (S-phase) and sometimes block cells from progressing from the G1 phase to the S-phase.[1][2][3]
Route: IT
Extravasation: irritant
- "In-line filters must not be used when administering DepoCyt."[1]
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Cytarabine liposomal (DepoCyt) patient drug information (Chemocare)[4]
- Cytarabine liposomal (DepoCyt) patient drug information (UpToDate)[5]
References
- ↑ 1.0 1.1 1.2 Cytarabine liposomal (DepoCyt) package insert
- ↑ Cytarabine liposomal (DepoCyt) package insert (locally hosted backup)
- ↑ Depocyt manufacturer's website
- ↑ Cytarabine liposomal (DepoCyt) patient drug information (Chemocare)
- ↑ Cytarabine liposomal (DepoCyt) patient drug information (UpToDate)